Preliminary Analysis of Recurrent/Metastatic Nasopharyngeal Carcinoma Patients: a Phase II Study
Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
programmed cell death-1 (PD-1) inhibitors has been recommended as the first-line treatment
for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), but progression-free survival
(PFS) and overall survival (OS) was still unsatisfactory. Basic studies have already
confirmed PD-1 inhibitors had concurrent synergistic effect with chemotherapy and
radiotherapy. Few studies concerned about the treatment pattern for concurrent PD-1
inhibitors combination with chemoradiation for R/M NPC. There was still much uncertainties
about the timing, fraction dose and total dose for PD-1 inhibitors combination with
radiation. Therefore, we aimed to explore the substantial effect and toxicity of this new
pattern for R/M NPC.